https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png

North America Biologics CMO Data

bt_bb_section_bottom_section_coverage_image

Overview

Explore over 150 North America-based contract manufacturing organizations engaged in the contract services of manufacturing biologics products including antibodies, vaccines, recombinant products, cell & gene therapy products among others, starting from cell-line development to fill & finish.

The data provides detailed insights that are available nowhere in the market with the goal of assisting market players in advancing their priorities and investments, as well as accessing the competitive landscape.

The data is captured around 25 vital metrics including biologics manufacturer’s name, location, service offering capabilities, scale of manufacturing, technology platforms, products and subproducts manufactured, current & completed projects of CMOs, facility name, location, establishment year, facility size & capacity, annual production, batch size, bioprocessing equipment, bioreactors, expression system, manufacturing process type, regulatory compliance & certifications, sponsors & collaborations, future plans of CMOs and many other parameters. Complete list of parameters is provided in the following section.

High number of biologics manufacturing facilities in the US, makes North America the most dominating globally. The North America CMO market has about 31% of the global CMO capacity with largest segment held by process development service. Some of the key Biologics CMOs covered in this tracker are KBI Biopharma Inc, FloridaBiologix, Cognate BioServices, MassBiologics, Goodwin Biotechnology, VGXI, In, Cytovance Biologics, Inc., and many other key CMOs operating in North America.

The data is underpinned by user-friendly visuals to allow users to filter through within all the parameters to obtain any specific data such as CMOs by country, CMOs name, product manufacturing type, scale of manufacturing, regulatory compliance, bioreactor capacity & types, service offerings, facility size, expression system, manufacturing process mode, analytical and bioprocessing equipment, collaborators, suppliers.

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/Overview-1.jpg

Pick the right plan!

From evolving customer expectations and emerging technologies to more nimble companies entering industries, businesses today are more at risk for disruption than ever before.
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png
6 Months
$3,640
  • Access for 6 months
  • Single user
  • Monthly Updates
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png
1 Year
$6,530
  • Access for 1 year
  • Single User
  • Monthly Updates

Key Parameters

  • Manufacturers Name
  • Manufacturers Location
  • Establishment Year
  • Service Offerings
  • Additional Services Offerings
  • Scale of Manufacturing (From pre-clinical to commercial)
  • Major Highlights
  • Technology Platform
  • Products Manufactured (All Biologics)
  • Sub-Products Manufactured
  • Projects
  • Investment (USD Mn)
  • Plant Name & Location
  • Facility Size (Square meters)
  • Plant Capacity & Batch Size
  • Bioreactor
  • Expression System
  • Manufacturing Process Type
  • Bioprocessing Equipment (Include technology service providers name)
  • Regulatory Compliance & Certifications
  • Sponsors & Collaborators
  • Expansion Plans & Other Updates
bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image

Regions Coverage

US, Canada
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/North-America-1280x494.jpg

Product Types Covered

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/Immunotherapeutic.jpg

Immunotherapeutic

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/Antibody-Therapeutics.jpg

Antibody Therapeutics

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-1.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/Cell-Therapy.jpg

Cell Therapy

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/Protein-Therapeutics.jpg

Protein Therapeutics

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/Gene-Therapy.jpg

Gene Therapy

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-1.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/Vaccines.jpg

Vaccines

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-3.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2021/06/img-floater-2.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/Blood-Plasma.jpg

Blood & Plasma

How This Data Will Benefit?

This data provides easy to comprehend data for over 150 biologics manufacturers with in-house capabilities and expert service offerings to support you with end-to-end manufacturing process. We ensure delivery of highly-qualified research as we tap into our database of 62000+ life science professionals curated over a decade.

The data provides extensive data and analyses of biologics-focused contract manufacturing service providers and their manufacturing facilities. Through this data IMAPAC aims to assist organizations to keep track of CMOs in North-America, particularly in the US, identify any opportunities for strategic partnership or investments to speed biologics product to market.

Through this data, you are more likely to stay ahead of your competitors by keeping updated track of new and upcoming CMOs, expand your knowledge & expertise in biomanufacturing. Identify any opportunities for strategic partnerships or investments to speed biologics products to market.

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/How-This-Tracker-Will-Benefit.png
https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/Data-Methodology.png

Data Methodology

The data is researched and validated using primary and secondary research. The data is collected through multiple scientific and non-scientific sources including live discussions with experts through IMAPAC’s events and research reports, survey polls, company websites, press releases, publicly available information, regulatory database and many more.

We have a database of key decision makers from the biopharma companies across the region. We host industry surveys with bioprocessing leaders of CMOs and Biopharma, and host primary interviews with Heads of Manufacturing, R&D, Process Development Heads and multiple stakeholders in the companies to gather data as well as validate that data using our primary research analysts.

Throughout the year, we keep in touch with the KOLs through telephonic Conversation, with Q&A sessions with high profile biopharma professionals, for example CSO/CTO profiles. Apart from telephonic conversations, we send a list of questions which these experts fill in detail and send back to us.

We have dedicated analysts who gather data. The data included is validated through primary research (interviews, phone calls) with stakeholders which is then validated by IMAPAC’s research analysts to ensure the accuracy of the data.

Key Questions Answered

  • Who are the key players in the biologics contract manufacturing market in the US and Canada?
  • Where are the largest facilities located for biologics clinical or commercial manufacturing?
  • What are the manufacturing services provided by the CMOs across North America?
  • Which key biologics are manufactured in CMO’s facility?
  • How many projects are completed by the CMOs?
  • What are the bioreactor capacities in manufacturing facility, process development labs? Is the capacity expandable?
  • Which CMO facilities in US offers end-to-end biomanufacturing capabilities?
  • Which are the key existing clients of CMOs and their client distribution regionally?
  • What is the strength of manufacturing team?
  • What type and model of equipment and technologies are used by CMOs?
  • Who is the technology or service providers of these CMOs?
  • Who are the current investors of CMOs and their facility?
  • What are the future expansion plans for CMOs in US and Canada?
bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image

Data Sample

https://biopharmamarketintelligence.imapac.com/wp-content/uploads/2022/07/APAC-Bioprocessing-768x521.jpg